ReviewPaediatric drugs2014
Hidradenitis suppurativa in children and adolescents: a review of treatment options.
Review in Paediatric drugs, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management.Journal of the American Academy of Dermatology · 2019Guideline
- Understanding the evolving treatment landscape of hidradenitis suppurativa: An analysis of All of Us.PloS one · 2025Article
- Hidradenitis suppurativa; classification, remedies, etiology, and comorbidities; a narrative review.Journal of family medicine and primary care · 2021Review
- Multidisciplinary Management of Adolescents with Hidradenitis Suppurativa - Series of Cases and Literature Review.Journal of multidisciplinary healthcare · 2021Article
- Clinical characteristics of pediatric hidradenitis suppurativa: a cross-sectional multicenter study of 140 patients.Archives of dermatological research · 2020Article
- [Endocrinological mechanisms in the pathophysiology of hidradenitis suppurativa].Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2020Review
- Consensus on the treatment of hidradenitis suppurativa - Brazilian Society of Dermatology.Anais brasileiros de dermatologia · 2019Article
- Long-Term Outcome of Adalimumab in a Young Girl with Hidradenitis Suppurativa.Skin appendage disorders · 2018Article
- Evidence-based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativa.Reviews in endocrine & metabolic disorders · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hidradenitis suppurativa (HS) is a burdensome disease and has the potential to affect the life course of patients. It is a rare disease in children, and the recorded literature is correspondingly scarce. This article reviews the therapeutic options for HS in children and adolescents, and highlights particular differences or challenges with treating patients in this age group compared with adults. The work-up of paediatric patients with HS should include considerations of possible endocrine co-morbidities and obesity. Medical therapy of lesions may include topical clindamycin. Systemic therapy may include analgesics, clindamycin and rifampicin, finasteride, corticosteroids or tumour necrosis factor alpha (TNFα) blockers. Superinfections should be appropriately treated. Scarring lesions generally require surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.